Cargando…
A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES”
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394429/ https://www.ncbi.nlm.nih.gov/pubmed/34337999 http://dx.doi.org/10.18553/jmcp.2021.27.8.1140 |
| _version_ | 1785083367277985792 |
|---|---|
| author | Kohli-Lynch, Ciaran N Ruiz-Negrón, Natalia Beal, Amy Bellows, Brandon K |
| author_facet | Kohli-Lynch, Ciaran N Ruiz-Negrón, Natalia Beal, Amy Bellows, Brandon K |
| author_sort | Kohli-Lynch, Ciaran N |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10394429 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Academy of Managed Care Pharmacy |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103944292023-08-03 A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” Kohli-Lynch, Ciaran N Ruiz-Negrón, Natalia Beal, Amy Bellows, Brandon K J Manag Care Spec Pharm Letters Academy of Managed Care Pharmacy 2021-08 /pmc/articles/PMC10394429/ /pubmed/34337999 http://dx.doi.org/10.18553/jmcp.2021.27.8.1140 Text en Copyright © 2021, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
| spellingShingle | Letters Kohli-Lynch, Ciaran N Ruiz-Negrón, Natalia Beal, Amy Bellows, Brandon K A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” |
| title | A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” |
| title_full | A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” |
| title_fullStr | A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” |
| title_full_unstemmed | A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” |
| title_short | A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES” |
| title_sort | response to: “cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes” |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394429/ https://www.ncbi.nlm.nih.gov/pubmed/34337999 http://dx.doi.org/10.18553/jmcp.2021.27.8.1140 |
| work_keys_str_mv | AT kohlilynchciarann aresponsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT ruiznegronnatalia aresponsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT bealamy aresponsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT bellowsbrandonk aresponsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT kohlilynchciarann responsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT ruiznegronnatalia responsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT bealamy responsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes AT bellowsbrandonk responsetocosteffectivenessoforalsemaglutideaddedtocurrentantihyperglycemictreatmentfortype2diabetes |